Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Michael L. Amalfitano, DO, FACC, FCCP, FACOI, is a cardiologist in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart & Vascular Institute. He is Director of Cardiovascular Services at Medina Hospital and has special interest in congestive heart failure, adult congenital heart disease and cardiac imaging, including nuclear cardiology and echocardiography. Dr. Amalfitano is board-certified in cardiology, critical care medicine and nuclear cardiology.
He is a graduate of the Philadelphia College of Osteopathic Medicine, Philadelphia, Pa. where he was a member of the Lambda Omicron Gamma Medical Society. He served his residency at the Osteopathic Medical Center of Philadelphia where he achieved the distinction of being Chief Resident. He completed fellowships in cardiovascular medicine at the Deborah Heart and Lung Center in Browns Mills, N.J. and in nuclear medicine at Temple University Hospital, Philadelphia.
Following completion of his training Dr. Amalfitano was Director of the Medical Intensive Care Unit and Coronary Care Unit and an attending cardiologist at Deborah Heart and Lung Center. He later completed a fellowship/preceptorship in intraoperative transesophageal echocardiography (an advanced type of cardiac imaging) at Cleveland Clinic.
Prior to joining the Cleveland Clinic staff, Dr. Amalfitano was a senior partner and attending cardiologist with the Mid-Ohio Heart Clinic and Medical Director of the MedCentral Health System Congestive Heart Failure Clinic. He also served as Director of the Section of Cardiovascular Imaging and Radiation Safety Officer for the Mid-Ohio Heart Clinic. His prior positions include Chairman, Division of Cardiology and Chairman, Department of Internal Medicine at Mid-Ohio and President/Chief of Staff and member of the Board of Trustees at MedCentral.
Dr. Amalfitano has been Principal Investigator and Regional Investigator on a number of significant studies related to heart failure, myocardial infarction (heart attack) and coronary artery disease. He has presented more than 50 Grand Rounds and local and national conference lectures and is a speaker for the American Heart Association and the American Dental Association.
He is a member of the American Osteopathic Association, the American Society of Echocardiography and the American Medical Association and a Fellow of the American College of Osteopathic Internists, the American College of Cardiology and the American College of Chest Physicians. Dr. Amalfitano is a founding member of the American Society of Nuclear Cardiology and the Society of Cardiovascular Computed Tomography. He also is a founding member of the State Medical Board of Ohio Quality Intervention Panel and currently serves as the panel’s Chairman.
Congestive heart failure, adult congenital heart disease, preventive cardiology and cardiac rehabilitation. cardiac imaging, including nuclear cardiology, transthoracic and transesophageal echocardiography Congestive heart failure, adult congenital heart disease, cardiac imaging, nuclear cardiology, echocardiogram-TEE
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/1/2015, Dr. Amalfitano has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.